Biocure Technology Inc.
CUREX
CNSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -44.49% | 471.74% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -44.49% | 471.74% | |||
| Operating Income | 44.49% | -471.74% | |||
| Income Before Tax | 39.82% | -118.71% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 39.82% | -118.71% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 39.82% | -118.71% | |||
| EBIT | 44.49% | -471.74% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 52.38% | -61.54% | |||
| Normalized Basic EPS | 53.85% | -62.50% | |||
| EPS Diluted | 52.38% | -61.54% | |||
| Normalized Diluted EPS | 53.85% | -62.50% | |||
| Average Basic Shares Outstanding | 25.78% | 32.57% | |||
| Average Diluted Shares Outstanding | 25.78% | 32.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||